Journal of Hematology & Oncology

Article	Citations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity	692
Targeting the Wnt/β-catenin signaling pathway in cancer	651
Nanomaterials for cancer therapy: current progress and perspectives	500
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	483
EZH2: a novel target for cancer treatment	456
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer	373
NK cell-based cancer immunotherapy: from basic biology to clinical development	321
Next generation of immune checkpoint inhibitors and beyond	304
Regulation of PD-L1 expression in the tumor microenvironment	292
Roles of METTL3 in cancer: mechanisms and therapeutic targeting	277
cGAS-STING, an important pathway in cancer immunotherapy	260
Challenges and advances in clinical applications of mesenchymal stromal cells	256
Cancer vaccines as promising immuno-therapeutics: platforms and current progress	240
RNA sequencing: new technologies and applications in cancer research	237
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)	233
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy	231
Isolation and characterization of exosomes for cancer research	217
Combination strategies to maximize the benefits of cancer immunotherapy	216
Dendritic cell biology and its role in tumor immunotherapy	210
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy	207
Immunosenescence: a key player in cancer development	206
Targeting mutant p53 for cancer therapy: direct and indirect strategies	206
Novel therapies emerging in oncology to target the TGF-β pathway	203
Targeting hypoxic tumor microenvironment in pancreatic cancer	199
Neutrophils in cancer carcinogenesis and metastasis	198

The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	194
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	194
Recent advances in CAR-T cell engineering	192
Applications of single-cell sequencing in cancer research: progress and perspectives	187
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells	186
Liquid biopsy: current technology and clinical applications	183
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response	181
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	179
Recent advances in therapeutic strategies for triple-negative breast cancer	179
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions	178
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy	169
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research	169
Oncolytic viruses for cancer immunotherapy	165
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma	163
Emerging therapeutic agents for advanced non-small cell lung cancer	161
RNA-binding proteins in tumor progression	157
Targeting CD47 for cancer immunotherapy	155
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study	155
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	151
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019	146
Targeting MCL-1 in cancer: current status and perspectives	146
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway	144
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti	143
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	142
MEK inhibitors for the treatment of non-small cell lung cancer	139
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	138
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	137
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	133
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies	132
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target	131
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	131
Antibody–drug conjugates in solid tumors: a look into novel targets	131
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends	130
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019	128
HMGB1 in inflammation and cancer	128
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis	127
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment	127
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape	123
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	122
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy	122
Modeling neoplastic disease with spheroids and organoids	122
XPO1-dependent nuclear export as a target for cancer therapy	116
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy	116
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	115
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies	115
Exploring immunotherapy in colorectal cancer	114
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017	112
Role of lysosomes in physiological activities, diseases, and therapy	110
Targeting autophagy to overcome drug resistance: further developments	110
Emerging agents that target signaling pathways in cancer stem cells	110

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy	108
Mesenchymal stem/stromal cells in cancer therapy	107
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential	107
The management of metastatic GIST: current standard and investigational therapeutics	107
How to select IgG subclasses in developing anti-tumor therapeutic antibodies	107
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	106
tRNA-derived RNA fragments in cancer: current status and future perspectives	106
BCMA-targeted immunotherapy for multiple myeloma	105
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies	104
Emerging agents and regimens for AML	103
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands	103
The potential role of N7-methylguanosine (m7G) in cancer	98
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions	98
Targeting Akt in cancer for precision therapy	98
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation	97
Emerging strategies to target RAS signaling in human cancer therapy	96
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward	95
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	94
Gene modification strategies for next-generation CAR T cells against solid cancers	94
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer	92
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma	91
The long and short non-coding RNAs modulating EZH2 signaling in cancer	91
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents	91
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma	91
The application and prospect of CDK4/6 inhibitors in malignant solid tumors	89
Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis	89
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia	89
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma	87
Targeting EphA2 in cancer	87
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment	84
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk	83
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC	82
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial	81
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	81
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks	81
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study	81
Gastric cancer treatment: recent progress and future perspectives	80
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	79
Role of CD47 in Hematological Malignancies	78
Novel therapies are changing treatment paradigms in metastatic prostate cancer	78
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA	77
New agents and regimens for diffuse large B cell lymphoma	75
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA	74
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	73
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers	72
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT	72
Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study	72
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia	71
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges	70
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	70
Prostate cancer and PARP inhibitors: progress and challenges	70
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	70
Crosstalks between inflammasome and autophagy in cancer	69
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	69
Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer	69
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors	68
Targeting immune checkpoints in hematological malignancies	67
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications	66
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer	66
Born to survive: how cancer cells resist CAR T cell therapy	65
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma	65
FGFR-TKI resistance in cancer: current status and perspectives	65
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	64
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials	64
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential	64
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas	64
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib	63
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies	63
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism	62
Third-line therapy for chronic myeloid leukemia: current status and future directions	60
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors	60
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study	60
Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application	60
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	59
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer	59
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors	59
Natural killer cell-based immunotherapy for acute myeloid leukemia	58
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management	58
Thrombocytopenia and thrombosis in hospitalized patients with COVID-19	58
Advances in the diagnosis and treatment of sickle cell disease	58

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity	58
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)	57
The emerging role of KDM5A in human cancer	56
Targeting macrophages in hematological malignancies: recent advances and future directions	55
Tumor organoids: applications in cancer modeling and potentials in precision medicine	55
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies	55
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study	55
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes	54
Emerging agents and regimens for multiple myeloma	54
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	54
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer	54
Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea	53
Emerging strategies to overcome resistance to third-generation EGFR inhibitors	53
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	53
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance	52
Prognostic and predictive biomarker developments in multiple myeloma	51
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	51
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party o	51
Beyond thrombosis: the impact of tissue factor signaling in cancer	51
Therapeutic strategies in RET gene rearranged non-small cell lung cancer	51
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies	51
CAR-T cells and BiTEs in solid tumors: challenges and perspectives	50
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer	50
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy	50
Molecular pathogenesis of the myeloproliferative neoplasms	50
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	49
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	49
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	49
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors	49
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	49
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials	48
Payload diversification: a key step in the development of antibody–drug conjugates	48
The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia	48
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals	47
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	47
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial	47
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer	47
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy	47
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	47
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	46
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matche	46
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities	46
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials	46
The functions and clinical significance of circRNAs in hematological malignancies	46
Protein degradation technology: a strategic paradigm shift in drug discovery	46
Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients	45
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer	45
A single-cell survey of cellular hierarchy in acute myeloid leukemia	45
Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism	45
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials	45
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies	44
Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma	44
Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer	44
Integrins regulate stemness in solid tumor: an emerging therapeutic target	44
How we treat NK/T-cell lymphomas	44
Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment	44
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients	43
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity	43
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma	43
Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data	43
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	42
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies	42
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	42
Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches	42
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers	41
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA	41
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)	41
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia	40
Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway	40
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN	40
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia	40
Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment	39
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	39
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress	39
Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma	39
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia	39
Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers	38
High-throughput approaches for precision medicine in high-grade serous ovarian cancer	38
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study	38
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	38
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes	38
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination	38
Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma	37
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia	37
Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets	37
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer	37
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	36
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	36
Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis	36
Drugging KRAS: current perspectives and state-of-art review	36
Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance	36
Novel targeted therapies of T cell lymphomas	35
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis	35
Targeting oncogenic Notch signaling with SERCA inhibitors	35
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia	35